Teva Pharmaceutical Industries (NYSE:TEVA) announced the pricing and early acceptance results of its previously announced tender offers to buy for cash the outstanding notes.
The disclosed debt tender offers were a strategic move aimed at managing its liabilities, optimizing its capital structure, and extending its debt maturity profile.
The tender offers were divided into three pools, each with a cap of $1.55B, $350M, and $400M.
The settlement date for accepted notes is set for June 5, 2025.
